(Total Views: 261)
Posted On: 10/05/2023 2:41:20 PM
Post# of 39319
This little-known NASDAQ carries a $21 price target and its CEO is buying up shares…
Atai Life Sciences (NASDAQ: ATAI)
The company has plenty of cash on hand to the tune of $227M as reported in the company’s last financial report. AND… the company has anticipated runway all the way into the first half of 2026!
First major collaboration between this type of biotech and a big pharma company!
ATAI currently has 8 clinical stage development programs with a focus on compound classes with prior evidence in humans; a portfolio approach to avoid binary risk and optimize the likelihood of success.
Read more in the FULL REPORT https://tradersnewssource.com/wp-content/uplo...rt-TNS.pdf
If you have not yet opted into our alerts by SMS/Text message then click here.
The Team
Atai Life Sciences (NASDAQ: ATAI)
The company has plenty of cash on hand to the tune of $227M as reported in the company’s last financial report. AND… the company has anticipated runway all the way into the first half of 2026!
First major collaboration between this type of biotech and a big pharma company!
ATAI currently has 8 clinical stage development programs with a focus on compound classes with prior evidence in humans; a portfolio approach to avoid binary risk and optimize the likelihood of success.
Read more in the FULL REPORT https://tradersnewssource.com/wp-content/uplo...rt-TNS.pdf
If you have not yet opted into our alerts by SMS/Text message then click here.
The Team
(0)
(0)
